Gridai Technologies Corp. (GRDX) — SEC Filings
Gridai Technologies Corp. (GRDX) — 50 SEC filings. Latest: 8-K/A (Apr 13, 2026). Includes 36 8-K, 5 10-Q, 3 S-1/A.
View Gridai Technologies Corp. on SEC EDGAR
Overview
Gridai Technologies Corp. (GRDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 19, 2025, GridAI Technologies Corp. entered into a material definitive agreement. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers. The fil
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bearish, 39 neutral, 3 mixed. The dominant filing sentiment for Gridai Technologies Corp. is neutral.
Filing Type Overview
Gridai Technologies Corp. (GRDX) has filed 1 8-K/A, 36 8-K, 5 10-Q, 3 S-1/A, 2 S-1, 1 DEF 14A, 1 10-K/A, 1 10-K with the SEC between Jun 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of GRDX's 48 recent filings, 11 were flagged as high-risk, 33 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$3,410,700 |
| EPS | -$0.75 |
| Cash Position | $2,517,218 |
| Total Assets | $135,370,340 |
| Total Debt | $45,808,262 |
Key Executives
- Jason D. Sawyer
- Dr. Jack Syage
- Richard Paolone
- Board of Directors
- management
- Dr. David J. Mazzo
- Dr. James R. Bianco
- Dr. Jonathan L. Cohen
- Ms. Sarah E. Empey
Industry Context
Entero Therapeutics operates in the biotechnology sector, characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is competitive, with companies often seeking strategic acquisitions or divestitures to optimize their portfolios and secure funding. Recent trends include consolidation and a focus on innovative therapies, but also increased scrutiny on financial sustainability.
Top Tags
material-agreement (8) · Biotechnology (6) · management-change (6) · corporate-governance (5) · corporate-action (5) · Pharmaceuticals (5) · SEC Filing (5) · financial-obligation (5) · financials (5) · company-name-change (5)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $3.41M | Reduced by 41.4% from $5.82M in 9M 2024 to $3.41M in 9M 2025 |
| Cash and Cash Equivalents | $2.52M | Increased from $163K at Dec 31, 2024, to $2.52M at Sep 30, 2025 |
| Accumulated Deficit | $205.8M | Increased from $202.4M at Dec 31, 2024, to $205.8M at Sep 30, 2025 |
| Assets Held-for-Sale | $83.17M | Represents the value of the IMGX subsidiary intended for disposal |
| Additional Paid-in Capital from Grid AI | $24.99M | Resulted from the issuance of Series H preferred stock upon Grid AI acquisition |
| Proceeds from Equity Offering | $3.03M | Net proceeds from issuance of common stock, prefunded warrants, and warrants in 9M 2025 |
| Research and Development Expenses | $32,080 | Decreased significantly from $882,522 in 9M 2024 to $32,080 in 9M 2025 |
| General and Administrative Expenses | $2.36M | Decreased substantially from $13.54M in 9M 2024 to $2.36M in 9M 2025 |
| Common Stock Shares Outstanding | 3,361,903 | As of November 18, 2025 |
| Loss per Share (Q3 2025) | $0.75 | Improved from $1.76 in Q3 2024 |
| Full-time Employees | 0 | As of September 9, 2025, down from 15, reflecting severe capital constraints. |
| ImmunogenX Unsecured Debt | $2.44M | Potential liability if the merger rescission is not consummated by October 31, 2025. |
| Shares Offered by Selling Stockholders | 4,945,510 | Represents potential dilution from warrant exercises, with no proceeds to the company. |
| Reverse Stock Split | 1-for-3 | Effective August 18, 2025, to maintain Nasdaq listing, but doesn't address underlying value. |
| Projected Cash Runway | April 2026 | Assuming successful financing efforts, which are not guaranteed. |
Frequently Asked Questions
What are the latest SEC filings for Gridai Technologies Corp. (GRDX)?
Gridai Technologies Corp. has 50 recent SEC filings from Jun 2024 to Apr 2026, including 36 8-K, 5 10-Q, 3 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GRDX filings?
Across 50 filings, the sentiment breakdown is: 8 bearish, 39 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Gridai Technologies Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Gridai Technologies Corp. (GRDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Gridai Technologies Corp.?
Key financial highlights from Gridai Technologies Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GRDX?
The investment thesis for GRDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Gridai Technologies Corp.?
Key executives identified across Gridai Technologies Corp.'s filings include Jason D. Sawyer, Dr. Jack Syage, Richard Paolone, Board of Directors, management and 4 others.
What are the main risk factors for Gridai Technologies Corp. stock?
Of GRDX's 48 assessed filings, 11 were flagged high-risk, 33 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Gridai Technologies Corp.?
Forward guidance and predictions for Gridai Technologies Corp. are extracted from SEC filings as they are enriched.